These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37858532)

  • 1. Fragment-based screening by protein-detected NMR spectroscopy.
    Kerber PJ; Nuñez R; Jensen DR; Zhou AL; Peterson FC; Hill RB; Volkman BF; Smith BC
    Methods Enzymol; 2023; 690():285-310. PubMed ID: 37858532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of 2D Difference Intensity Analysis for Chemical Library Screening by Protein-Detected NMR Spectroscopy.
    Egner JM; Jensen DR; Olp MD; Kennedy NW; Volkman BF; Peterson FC; Smith BC; Hill RB
    Chembiochem; 2018 Mar; 19(5):448-458. PubMed ID: 29239081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Kinase Production and Fragment Screening by NMR Spectroscopy.
    Han B; Ahn HC
    Methods Mol Biol; 2016; 1360():35-46. PubMed ID: 26501900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical aspects of NMR-based fragment screening.
    Lepre CA
    Methods Enzymol; 2011; 493():219-39. PubMed ID: 21371593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR quality control of fragment libraries for screening.
    Sreeramulu S; Richter C; Kuehn T; Azzaoui K; Blommers MJJ; Del Conte R; Fragai M; Trieloff N; Schmieder P; Nazaré M; Specker E; Ivanov V; Oschkinat H; Banci L; Schwalbe H
    J Biomol NMR; 2020 Nov; 74(10-11):555-563. PubMed ID: 32533387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR-based fragment screening and lead discovery accelerated by principal component analysis.
    Namanja AT; Xu J; Wu H; Sun Q; Upadhyay AK; Sun C; Van Doren SR; Petros AM
    J Biomol NMR; 2019 Dec; 73(12):675-685. PubMed ID: 31541395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of Solution NMR in Drug Discovery.
    Shi L; Zhang N
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A three-stage biophysical screening cascade for fragment-based drug discovery.
    Mashalidis EH; Śledź P; Lang S; Abell C
    Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR-Fragment Based Virtual Screening: A Brief Overview.
    Singh M; Tam B; Akabayov B
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29370102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiently driving protein-based fragment screening and lead discovery using two-dimensional NMR.
    Peng C; Namanja AT; Munoz E; Wu H; Frederick TE; Maestre-Martinez M; Iglesias Fernandez I; Sun Q; Cobas C; Sun C; Petros AM
    J Biomol NMR; 2023 Apr; 77(1-2):39-53. PubMed ID: 36512150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR screening in fragment-based drug design: a practical guide.
    Kim HY; Wyss DF
    Methods Mol Biol; 2015; 1263():197-208. PubMed ID: 25618347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics.
    Lau WF; Withka JM; Hepworth D; Magee TV; Du YJ; Bakken GA; Miller MD; Hendsch ZS; Thanabal V; Kolodziej SA; Xing L; Hu Q; Narasimhan LS; Love R; Charlton ME; Hughes S; van Hoorn WP; Mills JE
    J Comput Aided Mol Des; 2011 Jul; 25(7):621-36. PubMed ID: 21604056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting biomolecular NMR spectroscopy for promoting small-molecule drug discovery.
    Hanzawa H; Shimada T; Takahashi M; Takahashi H
    J Biomol NMR; 2020 Nov; 74(10-11):501-508. PubMed ID: 32306215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR spectroscopy: the swiss army knife of drug discovery.
    Horst R; Farley KA; Kormos BL; Withka JM
    J Biomol NMR; 2020 Nov; 74(10-11):509-519. PubMed ID: 32617727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR.
    Alvarado C; Stahl E; Koessel K; Rivera A; Cherry BR; Pulavarti SVSRK; Szyperski T; Cance W; Marlowe T
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31540099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [NMR screening in fragment-based drug discovery].
    Hanzawa H; Takizawa T
    Yakugaku Zasshi; 2010 Mar; 130(3):325-33. PubMed ID: 20190517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.